EUVIMEDEUVIMED entdecken
Open Access

Phenotypic discovery and therapeutic evaluation of an ITGA3B1 -targeting antibody-drug conjugate for bladder cancer

Junghyeon Lee iD, Hyeryeon Jung iD, Eunhee G Kim iD, Jinsung Ahn iD, Michael C Haffner iD, Peter S Nelson iD, Kwang Pyo Kim iD, John K Lee iD, Eugene C Yi iD, Kristine M Kim iD

Science Advances · 2026

DOI: 10.1126/sciadv.ady0041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Junghyeon Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Immunology, Division of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Re…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Immunoconjugates, Integrin alpha3beta1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Parker Institute for Cancer Immunotherapy, Kangwon National University, Kyung Hee University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) require antibodies with both high specificity and efficient internalization, features often overlooked by conventional discovery pipelines that rely on preselected antigens and recombinant proteins. Here, we describe an integrated phenotypic platform that combines target-unbiased live-cell biopanning with in situ chemical cross-linking and mass spectrometry to concurrently identify internalizing antibodies and their membrane-bound cognate antigens in a native cellular context. Using this approach, we identified 2E7, an antibody with rapid internalization and specificity for the integrin α3β1 ( ITGA3B1 ) heterodimer. Integrated transcriptomic and proteomic analyses revealed pronounced overexpression of ITGA3B1 across multiple solid tumors, with particularly elevated levels in aggressive bladder cancer subtypes. A 2E7-MMAE (monomethyl auristatin E) ADC exhibited potent, dose-dependent antitumor activity in bladder cancer xenograft models, leading to tumor regression and prolonging survival. This study establishes a generalizable framework for function-first ADC discovery and nominates ITGA3B1 as a promising therapeutic target in bladder cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsImmunoconjugatesIntegrin alpha3beta1HumansAnimalsCell Line, TumorMiceXenograft Model Antitumor AssaysOligopeptidesProteomicsDrug DiscoveryPhenotypeIntegrin alpha3

Substanzen

ImmunoconjugatesIntegrin alpha3beta1Oligopeptidesmonomethyl auristatin EIntegrin alpha3

Autor:innen und Institutionen

  • Department of Systems Immunology, Division of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Republic of Korea.
  • Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Republic of Korea.
  • Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
  • Department of Applied Chemistry, Department of Applied Chemistry, Institute of Natural Science, Kyung Hee University, Yongin, Republic of Korea.
  • Department of Biomedical Science and Technology, Kyung Hee Medical Science Research Institute, Kyung Hee University, Seoul, Republic of Korea.

ORCID-Profile: Junghyeon Lee, Hyeryeon Jung, Eunhee G Kim, Jinsung Ahn, Michael C Haffner, Peter S Nelson, Kwang Pyo Kim, John K Lee, Eugene C Yi, Kristine M Kim

Förderung

  • Parker Institute for Cancer Immunotherapy
  • Kangwon National University
  • Kyung Hee University
  • National Research Foundation of Korea
  • CDMRP
  • BK21 FOUR of the Ministry of Education
  • Department of Defense Peer-Reviewed Cancer Research Program
  • Bladder Cancer Advocacy Network Innovation Award

Zitieren

APA

Lee, J., Jung, H., Kim, E. G., Ahn, J., Haffner, M. C., Nelson, P. S., Kim, K. P., Lee, J. K., Yi, E. C., & Kim, K. M. (2026). Phenotypic discovery and therapeutic evaluation of an ITGA3B1 -targeting antibody-drug conjugate for bladder cancer. Science Advances. https://doi.org/10.1126/sciadv.ady0041

Vancouver

Lee J, Jung H, Kim EG, Ahn J, Haffner MC, Nelson PS, et al. Phenotypic discovery and therapeutic evaluation of an ITGA3B1 -targeting antibody-drug conjugate for bladder cancer. Science Advances. 2026. doi:10.1126/sciadv.ady0041

BibTeX
@article{Lee2026,
  author = {Lee, Junghyeon and Jung, Hyeryeon and Kim, Eunhee G and Ahn, Jinsung and Haffner, Michael C and Nelson, Peter S and Kim, Kwang Pyo and Lee, John K and Yi, Eugene C and Kim, Kristine M},
  title = {Phenotypic discovery and therapeutic evaluation of an ITGA3B1 -targeting antibody-drug conjugate for bladder cancer},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.ady0041}
}
Kostenlos starten →